IDO1 and neoplasm: Collectively, these findings indicate that the combination of ERO1a and IDO1 inhibition not only promotes antigen presentation pathways and DC infiltration but also broader anti-tumor immune effects, creating an inflamed tumor microenvironment conducive to mounting an effective immune response against PDAC.